Population-based study of islet cell carcinoma.
Population-based study of islet cell carcinoma.
复制标题
DOI：
10.1245/s10434-007-9566-6
复制
发表时间：
2007-12
影响因子：
3.7
通讯作者：
Evans DB
中科院分区：
文献类型：
--
作者：
Yao JC;Eisner MP;Leary C;Dagohoy C;Phan A;Rashid A;Hassan M;Evans DB
通过基于人群的登记，我们研究了影响胰岛细胞癌生存时间的流行病学、自然病史和预后因素。监测、流行病学和最终结果(SEER)计划数据库(1973-2003发布，2006年4月)用于根据组织学编码和肿瘤部位识别胰岛细胞癌病例。总共确定了1310例(619名女性和691名男性)病例，中位年龄为59岁。SEER第9期(1973-1991年)、SEER第13期(1992-1999年)和SEER第17期(2000-2003年)的年年龄调整发病率分别为0.16/10万、0.14/10万和0.12/10万。2003年1月1日，美国估计28年有限病程患病率为2705例。按SEER分期，局部性、区域性和远侧性分期分别占14%、23%和54%。中位生存期38个月。按分期，局部、局部和远处病变患者的中位生存期分别为124(95%CI，80-168)个月、70(95%CI，54-86)个月和23(95%CI，20-26)个月。通过多变量COX比例模型，发现分期(P<；.001)、原发肿瘤部位(P=.04)和确诊时年龄(P<；.001)是显著的生存预测因素。胰岛细胞癌约占胰腺癌的1.3%。大多数患者在确诊时已是晚期疾病。尽管这种疾病以懒惰著称，但晚期患者的存活期仅为2年。需要开发新的治疗方法。
We examine the epidemiology, natural history, and prognostic factors that affect the duration of survival for islet cell carcinoma by using population-based registries. The Surveillance, Epidemiology, and End Results (SEER) Program database (1973–2003 release, April 2006) was used to identify cases of islet cell carcinoma by histology codes and tumor site. A total of 1310 (619 women and 691 men) cases with a median age of 59 years were identified. The annual age-adjusted incidence in the periods covered by SEER 9 (1973–1991), SEER 13 (1992–1999), and SEER 17 (2000–2003) were .16, .14, and .12 per 100,000, respectively. The estimated 28-year limited duration prevalence on January 1, 2003, in the United States was 2705 cases. Classified by SEER stage, localized, regional, and distant stages corresponded to 14%, 23%, and 54% of cases. The median survival was 38 months. By stage, median survival for patients with localized, regional, and distant disease were 124 (95% CI, 80–168) months, 70 (95% CI, 54–86) months, and 23 (95% CI, 20–26) months, respectively. By multivariate Cox proportional modeling, stage (P < .001), primary tumor location (P = .04), and age at diagnosis (P < .001) were found to be significant predictors of survival. Islet cell carcinomas account for approximately 1.3% of cancers arising in the pancreas. Most patients have advanced disease at the time of diagnosis. Despite the disease’s reputation of being indolent, survival of patients with advanced disease remains only 2 years. Development of novel therapeutic approaches is needed.
登录
查看更多内容
影响因子：
158.5
作者：
MOERTEL, CG;LEFKOPOULO, M;KLAASSEN, D
通讯作者：
KLAASSEN, D
影响因子：
6.2
作者：
Modlin, IM;Lye, KD;Kidd, M
通讯作者：
Kidd, M
影响因子：
29.4
作者：
Lepage, Come;Rachet, Bernard;Coleman, Michel Philippe
通讯作者：
Coleman, Michel Philippe
影响因子：
29.4
作者：
Hammel, PR;Vilgrain, V;Richard, S
通讯作者：
Richard, S
Foregut（Neuro）内分泌肿瘤的TNM分期：包括分级系统在内的共识提案。
影响因子：
3.5
作者：
Rindi, G.;Kloeppel, G.;Alhman, H.;Caplin, M.;Couvelard, A.;de Herder, W. W.;Erikssson, B.;Falchetti, A.;Falconi, M.;Komminoth, P.;Koerner, M.;Lopes, J. M.;McNicol, A-M.;Nilsson, O.;Perren, A.;Scarpa, A.;Scoazec, J. -Y;Wiedenmann, B.
通讯作者：
Wiedenmann, B.